Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Panita who wrote (98300)	9/21/1999 3:53:00 PM
From: hotlinktuna	Read Replies (1) \| Respond to of 119973

looking for double digits tomorrow in *EDGR* good news today on ad blitz coming in October! tuna

To: Panita who wrote (98300)	9/21/1999 11:08:00 PM
From: Ron	Respond to of 119973

Big FDA approval for RP: UNTIL NOW, the last line of defense against the most aggressive bacterial infections has been the drug vancomycin - but germs are increasingly developing resistance to it. The elderly and people with weakened immune systems are most at risk. The need for a new antibiotic was so great that the Food and Drug Administration for the past year has allowed hundreds of patients at risk of death from drug-resistant germs to be treated with Synercid under a special emergency program, while the agency decided whether the drug was safe and effective enough for broad sale. Today, the FDA approved Synercid to treat vancomycin-resistant enterococcal infections, a life-threatening infection that strikes thousands of hospital patients. One recent study estimated as many as 52 percent of enterococcal infections are now vancomycin-resistant, making them difficult if not impossible to treat. Synercid, an intravenous antibiotic, will be available for doctors to prescribe beginning Oct. 1. Synercid, manufactured by Rhone-Poulenc Rorer,(RP) is the first in a new class of antibiotics called streptogamins to be sold in the United States, and it appears to work by dealing bacteria a one-two punch. It is a combination of two drugs - quinupristin and dalfopristin - that inhibit two different methods of bacterial protein synthesis. That combination effect makes the chemicals 16 times more potent together than either molecule alone, the company says.